MKC-442 Combined With Viracept in HIV-Infected Patients

Phase 3, randomised, double-blind trial of Emivirine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Triangle Pharmaceuticals, Inc. Primary endpoints: Proportion of patients with plasma HIV-1 RNA level < 400 copies/ml at 24 weeks and Proportion of patients with plasma HIV-1 RNA level < 50 copies/ml at 24 weeks. Status: completed.